Skip to main content
BBIO logo

BridgeBio Pharma, Inc. (BBIO) Stock: Price, Forecast & Analyst Target

BridgeBio Pharma, Inc. (BBIO) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $78.01 (+1.58%), as of the Nov 18, 2026 trading session; market cap $15.2B.

Educational signal · not a buy or sell recommendation · How to read this

$78.01 +$1.21 (+1.58%) Market Cap $15.2B

BridgeBio Pharma, Inc. · BBIO · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: BridgeBio Pharma is a genetic-disease pharmaceutical developer whose economics now combine product sales with licensing, services and royalties, while research programs span small molecules and gene therapy. The case depends on whether product-led gross profit can overtake a cost base that still produces operating losses and heavy cash use before financing pressure intensifies.

Price as of Nov 18, 2026

Key Statistics

20 of 100

MoonshotScore v2 · BridgeBio Pharma (BBIO)

Weak
Business Quality Average (51)
Financial Safety Strained (31)
Valuation Full (54)
Growth Durability Growing (69)
Momentum Rising (79)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Rising.

  • EPS beat 2 of the last 8 reports
  • Altman Z -0.01 · Piotroski F 2

Holding back: balance-sheet strain

Helping: durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BBIO (57 recorded, newest six shown)
RecordedScoreBand
21Weak
20Weak
21Weak
21Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$78.01
Change on the day+1.58%
52-week range$62.50–$93.42
Market capitalisation$15.2B—
Price / earnings (trailing)355.73
Shares traded on the day3.55M
Beta (volatility vs the S&P 500)0.97

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $54, high $86, latest $78. $86 $54 high $86 Oct 17, 2025 Nov 18, 2026 · $78 $55Oct 17, 2025$63Oct 31, 2025$66Nov 14, 2025$72Nov 28, 2025$75Dec 12, 2025$76Dec 26, 2025$77Jan 9, 2026$78Jan 23, 2026$68Feb 6, 2026$68Feb 20, 2026$65Mar 6, 2026$69Mar 20, 2026$73Apr 2, 2026$77Apr 17, 2026$69May 1, 2026$66May 15, 2026$66May 29, 2026$67Jun 12, 2026$70Jun 26, 2026$86Jul 10, 2026$84Jul 24, 2026$84Aug 7, 2026$82Aug 21, 2026$75Sep 4, 2026$67Sep 18, 2026$67Oct 2, 2026$66Oct 16, 2026$75Oct 30, 2026$78Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for BridgeBio Pharma (BBIO): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Weak
Valuation Neutral
Growth Durability Moderate
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is BridgeBio Pharma (BBIO), and what does it report?

Short answer · as of

BridgeBio identifies and advances therapies for genetic conditions, using disease-focused development programs alongside strategic licensing and collaboration agreements.

Its accounts now reflect a hybrid pharmaceutical business: product sales form the largest revenue stream, license and service income remains meaningful, and royalties contribute less. Revenue therefore increasingly measures commercial medicine sales alongside partner economics, rather than clinical progress alone.

2 · Latest results

What do the latest results show for BridgeBio Pharma (BBIO)?

Revenue and gross profit have risen through successive periods, and the latest earnings release again cleared the revenue expectation. Operating and net results nevertheless remained negative, while the per-share loss was worse than expected.

Product sales are the dominant reported stream, making commercial activity the clearest mechanism behind the higher revenue base. Research spending and selling, general and administrative costs remain large and recently increased, preventing gross profit from translating into operating profit.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$121M-$183M-$0.95 (diluted)
Q4 FY2025$154M-$193M-$1.00 (diluted)
Q1 FY2026$195M-$164M-$0.84 (diluted)
Q2 FY2026$244M-$152M-$0.78 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for BridgeBio Pharma (BBIO)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

BridgeBio retains high gross margins and current liquidity ratios above parity, which support a research-heavy operating model. Those strengths are constrained by debt exceeding cash and investments, recurring negative operating cash flow, and weak distress and quality screens.

The computed cash runway is short relative to the breadth of the development portfolio. If product growth fails to absorb research and commercial spending, BridgeBio may need additional financing while already carrying substantial debt, creating dilution or refinancing risk.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -0.01 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at BridgeBio Pharma (BBIO)?

Short answer · as of

Current published price targets run low $87.00 · high $156.00 · consensus $110.18 · median $107.00 against a quoted price of $78.01 (as of Nov 18, 2026).

The scheduled earnings release matters most for whether product-led revenue growth begins to narrow the operating loss. Published expectations call for higher revenue and a smaller per-share loss, while recent history shows that revenue can exceed expectations without comparable earnings improvement.

Watch cash consumed by operations, the cash balance, research spending and the trajectory of selling, general and administrative costs. Recent filings include material agreements and an unregistered equity issuance, making future financing terms relevant to dilution and balance-sheet risk.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does BridgeBio Pharma compare with its peers?

Short answer

BridgeBio Pharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

BridgeBio sits between a development-only biotechnology company and an established profitable pharmaceutical producer. It already records meaningful product revenue and very high gross margins, yet it continues to fund a broad genetic-disease pipeline while operating expenses exceed gross profit.

That combination makes commercial scaling and financing inseparable. Compared with development-only businesses, BridgeBio has a recurring product-sales engine; compared with mature pharmaceutical companies, it retains persistent losses, heavy cash use, a short computed runway and debt above liquidity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Named competitor$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
Jazz Pharmaceuticals plc (JAZZ) Named competitor$247.77 Nov 18, 2026$15.9B40 5-pillar Nov 18, 2026
BridgeBio Pharma (BBIO) — this page$78.01$15.2B20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$87.00 – $156.00
Consensus target
$110.18
Median target
$107.00

Consensus record · Captured .

Measured against a quoted price of $78.01 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 30, 2026

Transactions
88
Identified insiders
15
Purchases
0
Sales
34
Other transactions
54

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BBIO in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Viking GlobalAndreas HalvorsenQ3 20261.97%$644.33MTrimmed −1.6% shares
Bridgewater AssociatesFounded by Ray DalioQ3 20260.20%$45.77MAdded +55.2% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about BridgeBio Pharma (BBIO)?

Read these with our analysis →

Common Questions About BBIO (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What does BridgeBio sell beyond development rights?

Product sales are its largest revenue category, with license and service revenue adding a meaningful stream and royalties contributing less. Reported revenue therefore increasingly reflects commercial medicine sales rather than partner transactions alone.

Why is BridgeBio still losing money as product revenue rises?

Gross profit has expanded, but research spending and selling, general and administrative costs still exceed what the commercial base can support. Operating cash flow also remains negative, showing that revenue growth has not yet made the business self-funding.

What is BridgeBio's transthyretin stabilizer?

It is a small-molecule program designed to stabilize transthyretin for amyloidosis cardiomyopathy. The program exemplifies BridgeBio's approach of targeting the molecular cause of a genetic disease within a broader portfolio.

Can product sales fund BridgeBio's genetic-disease pipeline yet?

Current operations still consume cash despite expanding product revenue, so internal funding is not yet sufficient. Cash provides a buffer, but debt exceeds liquidity and the computed runway remains short.

What is the BBIO stock price today?

The last price recorded for BridgeBio Pharma, Inc. (BBIO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BBIO price target?

The analyst consensus price target for BridgeBio Pharma, Inc. (BBIO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 23 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Sector / industry (provider taxonomy); Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is BridgeBio Pharma (BBIO), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for BridgeBio Pharma (BBIO)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Revenue by segment; Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for BridgeBio Pharma (BBIO)?: Trailing twelve-month ratio set; Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Cash runway cross-check (ours); Cash against market value; Distress and quality screens; Business description
  • 4. What should you watch next at BridgeBio Pharma (BBIO)?: Next earnings report; Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Recent SEC filings
  • 5. How does BridgeBio Pharma compare with its peers?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash runway cross-check (ours)
  • FAQ: What does BridgeBio sell beyond development rights?: Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • FAQ: Why is BridgeBio still losing money as product revenue rises?: Quarterly income statement (USD thousands); Revenue by segment; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: What is BridgeBio's transthyretin stabilizer?: Business description
  • FAQ: Can product sales fund BridgeBio's genetic-disease pipeline yet?: Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.